Curative Biotechnology Inc

Curative Biotechnology, Inc. is a biopharmaceutical company that identifies, in-licenses, and develops therapeutic drug candidates for rare disease indications. Its pipeline includes Metformin Reformulation for intermediate dry macular degeneration and geographic atrophy, IMT504 for late-stage rabies, and CUBT906, a fully humanized CD56 monoclonal antibody carrying a cytotoxic drug conjugate to tumor sites. The company has a licensing and co-development agreement with Mid-Atlantic BioTherapeutics, Inc. for IMT504 and a development agreement with the University of Pennsylvania School of Veterinary Medicine for a metformin-based ophthalmic formulation. Founded in 1995, it is headquartered in Palm Beach Gardens, Florida.